• image

    the Phase 3 trial DIAGNODE-3

    and other ongoing trials

    Read More
  • image

    Developing precision therapies

    for type 1 diabetes

    VIDEO
  • image

    Intralymphatic immunotherapy

    with Diamyd®

    VIDEO

Press Releases 

Company Presentation

 October 9, 2024
Download PDF

DIAGNODE-3 stands as the only ongoing Phase 3 trial worldwide for a disease-modifying therapy in Type 1 Diabetes, placing Diamyd Medical at the forefront of innovative treatments.

image Ulf Hannelius
President and CEO, Diamyd Medical AB
CEO Comments, Year-End Report 23/24

Calendar

 Dates for financial information and other events
November 4 − November 8, 2024
IDS 2024
November 13, 2024
Barndiabetesfonden 35 years
November 14, 2024
Annual Report
Annual Report 2023/2024
December 5, 2024
Annual General Meeting
Annual General Meeting 2023/2024
January 29, 2025
Quarterly Report 1
Quarterly Report 1 2024/2025
April 9, 2025
Quarterly Report 2
Quarterly Report 2 2024/2025
June 25, 2025
Quarterly Report 3
Quarterly Report 3 2024/2025
October 8, 2025
Year-end Report
Year-end Report 2024/2025

The Story of Diamyd Medical

The company founder Anders Essen-Möller reveals the story behind the company's founding and his mission to stop type 1 diabetes in its tracks. The film also features board member Karin Hehenberger, shedding light on the patient’s perspective, and board member Dr. Mark Atkinson speaking of the importance of the enzyme GAD in type 1 diabetes.

“ If it was not for the hundreds of clinical sites and their personnel, investigators, patients, investors, not to mention the fantastic entrepreneurial, yet diligent, Diamyd team - this current transformational precision therapy for autoimmune diabetes based on genetics, should probably still remain undiscovered.
How can I thank you all ? "

- Anders Essen-Möller, Chairman of the Board

Manufacturing of GAD65 in Umeå

Image
A new facility for manufacturing of biological products is being set up in Umeå, the Capital of Västerbotten County in Sweden. The primary purpose is the manufacture of recombinant GAD65, the active pharmaceutical ingredient in the investigational medicine Diamyd®, an antigen-specific immunotherapy currently in late-stage clinical development.

Diamyd Medical has chosen Cytiva’s FlexFactory, a configurable single-use bioprocess platform for the manufacturing process that is based on a baculovirus-insect cell expression system.
Read More

THE COMPANY

Diamyd Medical develops therapies for type 1 diabetes
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)


Read More

Order GAD for preclinical research

ORDER

Annual Report

  November 29, 2023
Annual Report cover image
Download

Contact Us

Diamyd Medical AB (publ)
Box 7349, SE-103 90 Stockholm
Visiting addresses:
Kungsgatan 29, SE-111 56 Stockholm
+46 8 661 00 26
Umeå:
Formvägen 7B, SE-906 21 Umeå

Subscribe

Follow Us

  ©
GAD PRODUCTS
Order GAD for preclinical research